<DOC>
	<DOCNO>NCT01933529</DOCNO>
	<brief_summary>The purpose study determine whether non-hematopoietic erythropoietin analogue , ARA 290 , exert beneficial effect blood glucose level insulin secretion person prediabetes ( impaired glucose tolerance , IGT , impair fast glucose , IFG ) , drug-naive type 2 diabetes . The study also evaluate effect ARA 290 insulin sensitivity serum level inflammatory agent , e.g . cytokine . In addition , safety monitor follow parameter related hematology , kidney liver function lipid level .</brief_summary>
	<brief_title>ARA290 T2D ( Effects ARA 290 , Erythropoietin Analogue ) Prediabetes Type 2 Diabetes )</brief_title>
	<detailed_description>Aims study : The primary purpose double blind study determine individual pre-diabetes ( IGT , impair glucose tolerance ; IFG , impair fast glucose ) drug-naïve type 2 diabetes whether ARA 290 reduces disease activity improve oral glucose tolerance , insulin secretion , thereby improve long-term glucose control . Secondary objective evaluate effect ARA 290 insulin sensitivity ; serum level inflammatory agent , e.g . cytokine level ; serum level gluco-regulatory hormone , glucagon-like peptide-1 ( GLP-1 ) , glucagon ; safety registering report adverse event , monitor clinical chemistry parameter related hematology , kidney function , liver function lipid level . Study Design : This single-center , randomize , double-blind , placebo-controlled clinical trial evaluate effect ARA 290 glucose homeostasis person pre-diabetes early , dietary treat type 2 diabetes . The trial two parallel arm 12 subject group , 4-week-intervention period . At screening , baseline investigation include physical examination follow test : oral glucose tolerance test ( OGTT ) , glycosylated hemoglobin ( HbA1c ) . The investigational medicinal product ( ARA 290 , 4.0 mg ) placebo self-administered daily injection s.c. 28 day . Participating subject meet inclusion criterion , fulfil exclusion criterion screening , randomize double-blind within one week follow screen 1:1 either treatment ARA 290 placebo . Before first treatment , serum determination cytokine , adipokines , hormone collect . Participants investigate OGTT , HbA1c clinical assessment 2 week study end , 4 week . They also perform self-monitoring blood glucose ( SMBG ) curve weekly treatment period , e.g. , altogether 6 blood glucose test one day . Four week last dose , patient return HbA1c fast blood glucose level . The primary endpoint study test whether significant difference person receive ARA 290 vs. person receive placebo : glucose tolerance , evaluate OGTT baseline , 2 4 week . . The secondary endpoint study include effect ARA 290 : insulin sensitivity , evaluate HOMA-IR ( homeostasis model assessment insulin resistance ) ; insulin secretion , examine measure early insulin response ( 15 30 min ) OGTT , use HOMA-beta ( homeostasis model assessment beta cell function ) ; long-term glucose control , determine glycosylated hemoglobin , HbA1c ; assessment serum level inflammatory agent , e.g . cytokine level ; serum level gluco-regulatory hormone , glucagon-like peptide-1 ( GLP-1 ) , glucagon ; safety registering report adverse event , monitor clinical chemistry parameter related hematology , kidney function , liver function lipid level . Patients : 24 patient enrol one single center ; 12 patient administer ARA 290 active ingredient product daily dose 28 day , 12 patient administer placebo daily dose 28 day . Individuals IGT ( impaired glucose tolerance ) , IFG ( impaired fasting glucose ) drug-naïve type 2 diabetes include study . The population consist individual either gender , male age 40-75 year ; woman age 50-75 year menopausal .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Informed consent obtain prior trialrelated activity Meeting criterion impair fast glucose ( IFG ) , impair glucose tolerance ( IGT ) , IGF+IFG , type 2 diabetes screen OGTT . IFG = fast Pglucose 5.66.9 mmol/L 2 hr Pglucose &lt; 7.8 mmol/L ; IGT = fast Pglucose &lt; 5.6 mmol/L 2 hr Pglucose OGTT 7.811.0 mmol/L ; diabetes = fast Pglucose ≥ 7.0 mmol/L and/or 2 hr Pglucose ≥ 11.1 mmol/L . Fasting Pglucose ≤ 9 mmol/L . BMI ( body mass index ) ≤ 35 kg/m2 . Males age 4075 year ; woman age 5075 year menopause . Able read understand write consent form , complete studyrelated procedure , communicate study staff Refrigerator home storage study medication Anticipated change concomitant medication may interfere blood glucose homeostasis , systemic glucocorticoid , nonselective beta blocker anabolic steroid . Antidiabetic ( antihyperglycemic ) medication kind . Impaired renal function , define Screatinine ≥ 125 μmol/L men ≥ 115 μmol/L woman . Impaired hepatic function define plasma alanine aminotransferase ( PALT ) ≥ three time upper reference limit . Cardiac disease define unstable angina pectoris , myocardial infarction within last 6 month , congestive heart failure NYHA ( New York Heart Association ) class III IV . Cerebral stroke within last 6 month . Uncontrolled treat untreated hypertension ( systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg ) . Cancer diagnose and/or treat within last 5 year . Females childbearing potential . Known suspected abuse alcohol narcotic drug . Patients receive vaccination immunization within month prior screen The use AntiTNF ( antitumour necrosis factor ) therapy biological antiinflammatory agent administer within 3 month prior screen allow The use erythropoiesis stimulate agent within two month prior screen trial allow . Administration investigational drug trial 3 month prior administration initial dose investigational medicinal product 4 time per year .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>glucose tolerance</keyword>
	<keyword>insulin secretion</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>inflammation</keyword>
	<keyword>cytokine</keyword>
</DOC>